期刊
IMMUNOLOGY LETTERS
卷 229, 期 -, 页码 18-26出版社
ELSEVIER
DOI: 10.1016/j.imlet.2020.11.007
关键词
Multiple sclerosis; Bone mesenchymal stem cells; Experimental autoimmune encephalomyelitis; Lentivirus packaging system; MiR-23b
类别
资金
- National natural science foundation of China (key project) [81430035]
- national natural science foundation of China [81870955, 81771305]
Treatment with BMSCs over-expressing miR-23b in an experimental autoimmune encephalomyelitis mouse model demonstrated better therapeutic effects in inhibiting inflammation and delaying disease progression, possibly through modulating the Th17/Treg cell ratio and slowing spinal cord demyelination.
Bone marrow mesenchymal stem cells (BMSCs) have the immuno-modulatory capacity to ameliorate autoimmune diseases, such as multiple schlerosis (MS), systemic lupus erythematosus and rheumatoid arthritis. However, BMSC-mediated immunosuppression can be challenging to achieve. The efficacy of BMSC transplantation may be augmented by an adjuvant therapy. Here, we demonstrated that treatment of mice with experimental autoimmune encephalomyelitis (EAE), a model of MS, with BMSCs over-expressing microRNA (miR)-23b provided better synergistic and longer-term therapeutic effects than treatment with traditional BMSCs. Over-expression of miR-23b enhanced the ability of BMSCs to inhibit differentiation of Th17 cells and reduced IL-17 secretion. Compared to traditional BMSCs, the miR-23b over-expressing BMSCs (miR23b-BMSCs) exhibited enhanced secretion of tumor growth factor beta 1 (TGF-beta 1), a cytokine that promotes the differentiation of regulatory T (Treg) cells. Pathologically, miR23b-BMSC transplantation delayed EAE progression, apparently by reducing the Th17/Treg cell ratio and inhibiting inflammatory cell infiltration across the blood-brain barrier, and thus slowing spinal cord demyelination. These results may lead to better utility of BMSCs as a treatment for autoimmune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据